By selecting the Yes option, Leave Amgen.co.uk option, you understand that you are leaving the corporate page of Amgen UK and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Russell Abberley, Vice President and General Manager of Amgen UK and Ireland will formally take up the ABPI Presidency on 13 May for a period of two years.
CAMBRIDGE, UK (April 11, 2025) – Today, Amgen and the ABPI announced Russell Abberley, Vice President and General Manager of Amgen UK and Ireland, has been offically confirmed as ABPI President-elect, having held the role on an interim basis. He will formally take up the Presidency on 13 May for a period of two years, alongside his role at Amgen.
Russell will lead the ABPI in its mission to make the UK the best place in the world to research, develop and launch the medicines and vaccines of the future. His immediate focus will remain on delivering a thriving UK life sciences ecosystem, where patients can access innovative medicines and vaccines and where the right conditions exist to attract global investment.
He takes on the role at a pivotal moment, ahead of the publication of the NHS 10-Year Plan and the Life Sciences Sector Plan, confident in the role that industry can play in delivering on the Government’s ambitions for health and economic growth.
President-elect Russell Abberley said: “I am proud of the UK’s strong legacy of leadership in life sciences and innovation, however there’s more we can do to ensure that UK patients can access innovative treatments. A proud advocate for our sector, I stand ready to work with Government on delivering its ambition to make the UK a life sciences powerhouse. By working together, we can improve the health of the nation and generate much needed economic growth.”
Richard Torbett, ABPI Chief Executive said: “Russell has been great to work with as Acting President and is already a strong and valued member of our Board. I look forward to continuing our work together.”
Russell has more than 25 years of life science industry experience across a range of geographies. He has also served on the ABPI Board since July 2020 and has played a prominent leadership role in industry negotiations and engagements with the Government over the past five years.
NOTES TO EDITORS
About the Association of the British Pharmaceutical Industry (ABPI)
The ABPI exists to make
the UK the best place in the world to research, develop and access medicines and vaccines to improve patient
care.
We represent companies of all sizes which invest in making and discovering medicines and vaccines to enhance and save the lives of millions of people around the world.
In England, Scotland, Wales and Northern Ireland, we work in partnership with governments and the NHS so that patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, our members partner with healthcare professionals, academics and patient organisations to find new solutions to unmet health needs. www.abpi.org.uk